Hoffmann-la Roche Inc.

Merck Sharp + Dohme Corp.

F. Hoffmann-la Roche Ag

European Molecular Biology Laboratory

Savira Pharmaceuticals Gmbh

Chugai Pharmaceutical Co.

Chugai Seiyaku Kabushiki Kaisha

Sung-Sau So

Fariborz Firooznia

Francisco Javier Lopez-Tapia

Paul Gillespie

Achyutharao Sidduri

Li Chen

Yimin Qian

Amjad Ali

Hongying Yun

Jefferson Wright Tilley

Helmut Heinrich Buschmann

Mark Smith

Scott D Edmondson

Yun He

Ying-Duo Gao

Ronald Charles Hawley

Kin-Chun Thomas Luk

Nancy-Ellen Haynes

Alan W Hruza

Yan Lou

Shawn David Erickson

Peter Michael Wovkulich

Denis John Kertesz

Zhuyan Guo

Brian Alexander McKittrick

Zhicai Wu

Zhuming Zhang

Ramakanth Sarabu

Robert Alan Goodnow, Jr

John S Debenham

Allen John Lovey

Joseph P Lyssikatos

Jared N Cumming

Yi Heng Chen

Anandan Palani

Anthony A Estrada

Huifen Chen

Hongjun Zhang

Robert R Wilkening

David L Sloman

Javier De Vicente Fidalgo

Stefan Scheiblich

Lichun Feng

Timothy D Owens

Robert Francis Kester

Derun Li

James John Crawford

Tai-An Lin

Eric Mertz

Romyr Dominique

Kshitij Chhabilbhai Thakkar

Stephen Cusack

Rongze Kuang

Anthony K Ogawa

Weiguo Liu

Norman Kong

Wanying Sun

Hongju Li

Sherrie Lynn Pietranico-Cole

Christine E Brotherton-Pleiss

Jacqueline D Hicks

Heping Wu

Peter Orth

Santhosh Francis Neelamkavil

Kyungjin Kim

Linda Brockunier

Brent Whitehead

Giacomo Pizzolato

Jin-Jun Liu

Binh Vu

Roland Joseph Billedeau

Bruno Giethlen

Rama K Kondru

Abdelghani Achab

Xin-Jie Chu

Nathan Robert Scott

Qingjie Ding

Wendy Lea Corbett

Shaoqing Chen

Blaise S Lippa

Christian Fischer

Yu Jiang

Charles A Lesburg

Matthew Lloyd Childers

Ashwin Umesh Rao

Kevin Richard Guertin

Hakan Gunaydin

Qinglin Pu

Jing Zhang

Adrian Wai-Hing Cheung

Lan Wei

Min Lu

Tingting Yu

Steven Joseph Berthel

Bradford Graves

Dexi Yang

Chunsing Li

David Joseph Bartkovitz

Ping Lan

Saul Jaime-Figueroa

The present invention provides a compound of Formula (I) and pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing thromboses, embolisms, hypercoagulability or fibrotic changes. The compounds are selective Factor XI activation inhibitors.

Factor XI activation inhibitors

Described herein are compounds of Formula I or a pharmaceutically acceptable salt thereof. The compounds of Formula I act as arginase inhibitors and can be useful in preventing, treating or acting as a remedial agent for arginase-related diseases.

Arginase inhibitors and methods of use

This application discloses compounds according to generic Formula (I): wherein all variables are defined as described herein, which inhibit Btk. The compounds disclosed herein are useful to modulate the activity of Btk and treat diseases associated with excessive Btk activity. The compounds are useful for the treatment of oncological, auto-immune, and inflammatory diseases caused by aberrant B-cell activation. Also disclosed are compositions containing compounds of Formula (I) and at least one carrier, diluent or excipient. 

Inhibitors of bruton's tyrosine kinase

The present invention provides a compound of Formula I and pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing thromboses, embolisms, hypercoagulability or fibrotic changes. The compounds are selective Factor XIIa inhibitors. 

Factor XIIa inhibitors

The present invention provides a compound of Formula (I) and pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing thromboses, embolisms, hypercoagulability or fibrotic changes. The compounds are selective Factor XIIa inhibitors. 

The present invention provides a compound of Formula (I) and pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing thromboses, embolisms, hypercoagulability or fibrotic changes. The compounds are selective Factor XIa inhibitors or dual inhibitors of Factor XIa and plasma kallikrein. 

Factor XIa inhibitors

The present invention provides a compound of Formula (I); and pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing thromboses, embolisms, hypercoagulability or fibrotic changes. The compounds are selective Factor XIa inhibitors or dual inhibitors of Factor XIa and plasma kallikrein. 

The present invention provides a compound of Formula (I) and pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing thromboses, embolisms, hypercoaguability or fibrotic changes. The compounds are selective Factor XIa inhibitors or dual inhibitors of Factor XIa and plasma kallikrein. 

The present invention provides a compound of Formula (I) (Formula (I)) and pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing thromboses, embolisms, hypercoagulability or fibrotic changes. The compounds are selective Factor XIa inhibitors or dual inhibitors of Factor XIa and plasma kallikrein. 

This application discloses compounds according to generic Formula (I): wherein all variables are defined as described herein, which inhibit Btk. The compounds disclosed herein are useful to modulate the activity of Btk and treat diseases associated with excessive Btk activity. The compounds are useful for the treatment of oncological, auto-immune, and inflammatory diseases caused by aberrant B-cell activation. Also disclosed are compositions containing compounds of Formula I and at least one carrier, diluent or excipient. 

The present invention provides a compound of Formula I (The chemical formula should be inserted here.) and pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing thromboses, embolisms, hypercoagulability or fibrotic changes. The compounds are selective Factor XIa inhibitors or dual inhibitors of Factor XIa and plasma kallikrein. 

Factor Xla inhibitors

Growing community of inventors

Verona, NJ, United States of America

Sung-Sau So